Showing results (31-40 of 76) with videos related to
Sort By:
Pageof 8
Mini Reviews in Medicinal Chemistry|July 29, 2004
The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammationVito Ferro, Edward Hammond, Jon K FairweatherThe Journal of Clinical Investigation|December 10, 2015
Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activationTodd V Brennan, Liwen Lin, Joshua D Brandstadter, et al.Analytical Biochemistry|September 15, 2009
Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screeningEdward Hammond, Cai Ping Li, Vito FerroJournal of Medicinal Chemistry|February 5, 2010
Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growthKen D Johnstone, Tomislav Karoli, Ligong Liu, et al.Molecular Cancer Therapeutics|May 23, 2013
PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancerKatherine T Ostapoff, Niranjan Awasthi, Bercin Kutluk Cenik, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2002
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunityKeith Dredge, J Blake Marriott, Stephen M Todryk, et al.Blood|July 5, 2012
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantationTodd V Brennan, Liwen Lin, Xiaopei Huang, et al.Bioorganic & Medicinal Chemistry|October 31, 2007
Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88Jon K Fairweather, Edward Hammond, Ken D Johnstone, et al.Organic & Biomolecular Chemistry|August 19, 2007
Enantiospecific synthesis of the heparanase inhibitor (+)-trachyspic acid and stereoisomers from a common precursorSteven C Zammit, Vito Ferro, Edward Hammond, et al.British Journal of Clinical Pharmacology|July 10, 2023
The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndromeEne I Ette, Emmanuel O Fadiran, Christopher Missling, et al.Pageof 8